- Clinically meaningful activity of RM-1929 Photoimmunotherapy in patients with locoregional, recurrent head and neck cancer
- Generally well-tolerated treatment results and an overall response rate of 43 percent (95 percent CI 25.5-62.6)
- Initiates Phase 3 clinical trial to evaluate efficacy and safety of ASP-1929 Photoimmunotherapy versus standard-of-care
Chicago – June 1, 2019 – Rakuten Medical, a clinical-stage biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy (PIT) platform, announces positive data results from its Phase 2a study, evaluating the safety and anti-tumor activity of RM-1929 (an EGFR-targeted antibody conjugate) PIT in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC). Details of its global Phase 3 study trial design were also presented…Click here to read more.